|
| Tuesday, March 31, 2026 |
|
|
康希諾生物扭虧為盈 創新疫苗龍頭步入價值兌現期 |
| 日前，2026年兩會政府工作報告明確提出打造生物醫藥等新興支柱產業，中國創新醫藥行業正迎來政策春風。 more info >> |
|
|
康希诺生物扭亏为盈 创新疫苗龙头步入价值兑现期 |
| 日前，2026年两会政府工作报告明确提出打造生物医药等新兴支柱产业，中国创新医药行业正迎来政策春风。 more info >> |
|
|
CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader |
| China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability and highlighting steady progress in its commercialization efforts. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CanSinoBIO's Menhycia(R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential |
| CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the 'NMPA'), pursuant to which, the supplemental application to expand the age range of applicable population of the Company's Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the 'MCV4', trade name: Menhycia (R)) from 'children aged from 3 months to 3 years old (47 months)' to 'children aged from 3 months to 6 years old (83 months)' has been approved by NMPA. more info >> |
|
|
康希諾生物曼海欣(R)擴齡正式獲批 為公司長期價值開啟更廣闊發展空間 |
| 2026年2月24日，康希諾生物（688185.SH/06185.HK）宣佈，公司自主研發的ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）——曼海欣(R)擴大適用人群的補充申請已正式獲得國家藥品監督管理局批准。 more info >> |
|
|
康希诺生物曼海欣(R)扩龄正式获批 为公司长期价值开启更广阔发展空间 |
| 2026年2月24日，康希诺生物（688185.SH/06185.HK）宣布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）——曼海欣(R)扩大适用人群的补充申请已正式获得国家药品监督管理局批准。 more info >> |
|
| Wednesday, August 20, 2025 |
|
|
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle |
| In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. more info >> |
|
|
創新疫苗引擎持續驅動 康希諾開啟新增長週期 |
| 2025年上半年，醫藥行業結構性轉型持續深化，在政策利好、產品升級與技術革新的共同推動下，疫苗產業呈現出穩中向好的發展態勢。 more info >> |
|
|
创新疫苗引擎持续驱动 康希诺开启新增长周期 |
| 2025年上半年，医药行业结构性转型持续深化，在政策利好、产品升级与技术革新的共同推动下，疫苗产业呈现出稳中向好的发展态势。作为中国创新疫苗领域的领军企业，康希诺生物（上交所代码：688185.SH，联交所代码：6185.HK）再度交出一份稳健发展的成绩单。 more info >> |
|
| Saturday, June 21, 2025 |
|
|
康希諾重磅推出優佩欣疫苗 為兒童健康保駕護航的創新之選 |
| 在看似平靜的日常生活中，一種名為「肺炎球菌」的細菌正悄然威脅著兒童的健康。這種在人體鼻咽部「潛伏」的條件致病菌，平時可能毫無症狀，但一旦免疫力下降便會興風作浪，引發一系列疾病。 more info >> |
|
|
|
|
